Amended Current Report Filing (8-k/a)
August 09 2017 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 8, 2017
BIOSCRIP, INC.
(Exact name of Registrant as specified in
its charter)
Delaware
|
|
001-11993
|
|
05-0489664
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1600 Broadway, Suite 700, Denver, Colorado
|
|
80202
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (720) 697-5200
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Explanatory Note
BioScrip, Inc. (the
“Company”) is filing this Amendment No. 1 on Form 8-K/A to amend the Company’s Form 8-K, originally
filed with the Securities and Exchange Commission on August 8, 2017 (the “Original Filing”), to update the guidance
reconciliation table included in its earnings release issued on August 8, 2017 and furnished as an original exhibit to the Original
Filing.
Item 2.02. Results of Operations and
Financial Condition.
On August 8,
2017, the Company issued a press release reporting its 2017 second quarter financial results (the “Original Earnings
Release”), which was furnished as an exhibit to the Company’s Current Report on Form 8-K filed on August 8,
2017. The Company is hereby revising the Original Earnings Release (the “Revised Earnings Release”) to replace
the Schedule 5 included therein with a revised schedule that includes “Loss on Extinguishment of Debt” as a line
item in the reconciliation table and revises the number of weighted-average diluted shares. No other changes to the Original
Earnings Release were made. The Revised Earnings Release replaces the Original Earnings Release and has been re-posted on the
Company’s website. A copy of the Revised Earnings Release is furnished as Exhibit 99.1 to this
Form 8-K/A.
The Revised Earnings
Release includes certain non-GAAP financial measures as described therein. As required by Regulation G, reconciliation between
any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.
Item 9.01. Financial Statements and
Exhibits
(d) Exhibits
See the Exhibit Index, which is hereby incorporated
by reference.
As provided in General
Instruction B.2 to Form 8-K, the information furnished in Item 2.02 and in Exhibit 99.1 hereto, as it relates to the Company’s
financial results for the quarter ended June 30, 2017, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that
Section and shall not be deemed incorporated by reference into any filing of the Company with the Securities and Exchange Commission
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly provided by specific reference
in such filing
.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BIOSCRIP, INC.
|
|
|
|
Date: August 8, 2017
|
|
|
|
/s/ Kathryn Stalmack
|
|
|
By:
|
|
Kathryn Stalmack
|
|
|
|
|
Senior Vice President, General Counsel and Secretary
|
Exhibit
Index
Exhibit No.
|
|
Description
|
99.1
|
|
Revised Press Release dated August 8, 2017
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Sep 2023 to Sep 2024